Moderna (MRNA) Stock Forecast, Price Target & Predictions
MRNA Stock Forecast
Moderna stock forecast is as follows: an average price target of $143.90 (represents a 168.77% upside from MRNA’s last price of $53.54) and a rating consensus of 'Hold', based on 25 wall street analysts offering a 1-year stock forecast.
MRNA Price Target
The average price target for Moderna (MRNA) is $143.90 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $304.00 to $55.00. This represents a potential 168.77% upside from MRNA's last price of $53.54.
MRNA Analyst Ratings
According to 25 Wall Street analysts, Moderna's rating consensus is 'Hold'. The analyst rating breakdown for MRNA stock is 0 'Strong Buy' (0.00%), 9 'Buy' (36.00%), 15 'Hold' (60.00%), 1 'Sell' (4.00%), and 0 'Strong Sell' (0.00%).
Moderna Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Courtney Breen | Bernstein | $55.00 | $57.46 | -4.28% | 2.73% |
| Oct 14, 2024 | Michael Yee | Jefferies | $55.00 | $57.73 | -4.73% | 2.73% |
| Sep 13, 2024 | Edward Tenthoff | Piper Sandler | $115.00 | $69.68 | 65.04% | 114.79% |
| Sep 13, 2024 | Luca Issi | RBC Capital | $75.00 | $69.68 | 7.63% | 40.08% |
| Sep 13, 2024 | Leah Rush Cann | Loop Capital Markets | $238.00 | $69.68 | 241.56% | 344.53% |
| Sep 12, 2024 | Michael Yee | Jefferies | $65.00 | $69.68 | -6.72% | 21.40% |
| Sep 12, 2024 | Cory Kasimov | Evercore ISI | $105.00 | $67.68 | 55.14% | 96.12% |
| Sep 12, 2024 | Matthew Harrison | Morgan Stanley | $94.00 | $67.51 | 39.24% | 75.57% |
| Sep 12, 2024 | Michael Yee | Jefferies | $120.00 | $67.52 | 77.74% | 124.13% |
| Aug 28, 2024 | Peter Arment | Robert W. Baird | $220.00 | $78.52 | 180.18% | 310.91% |
The latest Moderna stock forecast, released on Oct 17, 2024 by Courtney Breen from Bernstein, set a price target of $55.00, which represents a -4.28% decrease from the stock price at the time of the forecast ($57.46), and a 2.73% increase from MRNA last price ($53.54).
Moderna Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 13 | 32 |
| Avg Price Target | $55.00 | $107.23 | $127.94 |
| Last Closing Price | $53.54 | $53.54 | $53.54 |
| Upside/Downside | 2.73% | 100.28% | 138.96% |
In the current month, the average price target of Moderna stock is $55.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 2.73% increase as opposed to Moderna's last price of $53.54. This month's average price target is down -48.71% compared to last quarter, and down -57.01% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 21, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Oct 17, 2024 | Bernstein | - | Market Perform | Initialise |
| Oct 15, 2024 | Sandler O'Neill | Sector Perform | Sector Perform | Hold |
| Oct 15, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Oct 14, 2024 | Jefferies | Hold | Hold | Hold |
| Sep 13, 2024 | Sandler O'Neill | Sector Perform | Sector Perform | Hold |
| Sep 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 13, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
| Sep 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Moderna's last stock rating was published by Piper Sandler on Oct 24, 2024. The company gave MRNA a "Overweight" rating, the same as its previous rate.
Moderna Financial Forecast
Moderna Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.83B | $344.00M | $1.86B | $5.08B | $3.22B | $4.57B | $5.94B | $7.21B | $4.97B | $4.35B | $1.94B | $570.75M | $157.91M | $66.35M | $8.39M | $14.05M | $17.05M |
| Avg Forecast | $1.51B | $1.30B | $114.70M | $160.30M | $1.39B | $1.21B | $219.51M | $264.63M | $1.56B | $1.24B | $128.41M | $93.26M | $2.51B | $1.38B | $307.67M | $1.18B | $5.02B | $3.53B | $4.10B | $4.20B | $6.80B | $6.08B | $4.21B | $2.05B | $279.41M | $80.60M | $27.51M | $17.60M | $17.37M | $17.64M |
| High Forecast | $1.51B | $1.30B | $114.70M | $160.30M | $1.39B | $1.21B | $219.51M | $264.63M | $1.56B | $1.49B | $128.41M | $93.26M | $2.91B | $1.92B | $307.67M | $1.18B | $5.02B | $3.53B | $4.10B | $4.20B | $6.80B | $6.08B | $4.21B | $2.05B | $279.41M | $80.60M | $27.51M | $17.60M | $17.37M | $17.64M |
| Low Forecast | $1.51B | $1.30B | $114.70M | $160.30M | $1.39B | $1.21B | $219.51M | $264.63M | $1.56B | $837.73M | $128.41M | $93.26M | $2.21B | $509.40M | $307.67M | $1.18B | $5.02B | $3.53B | $4.10B | $4.20B | $6.80B | $6.08B | $4.21B | $2.05B | $279.41M | $80.60M | $27.51M | $17.60M | $17.37M | $17.64M |
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 9 | 10 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.12% | 1.58% | 1.01% | 0.91% | 1.11% | 1.41% | 1.06% | 0.82% | 1.03% | 0.94% | 2.04% | 1.96% | 2.41% | 0.48% | 0.81% | 0.97% |
Moderna's average Quarter revenue forecast for Dec 23 based on 10 analysts is $2.51B, with a low forecast of $2.21B, and a high forecast of $2.91B. MRNA's average Quarter revenue forecast represents a 37.14% increase compared to the company's last Quarter revenue of $1.83B (Sep 23).
Moderna EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 9 | 10 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.01B | $-1.87B | $-288.00M | $1.58B | $1.34B | $2.45B | $4.32B | $5.49B | $3.63B | $3.14B | $1.28B | $-259.80M | $-221.44M | $-107.09M | $-115.05M | $-112.35M | $-114.56M |
| Avg Forecast | $-382.03M | $-329.98M | $-29.04M | $-40.58M | $-351.48M | $-307.45M | $-55.57M | $-67.00M | $-395.65M | $-314.78M | $-32.51M | $-23.61M | $-635.74M | $-350.51M | $-77.89M | $-298.26M | $-1.27B | $-859.55M | $-998.59M | $3.69B | $-1.66B | $-1.48B | $-1.03B | $1.04B | $-68.10M | $-19.65M | $-6.71M | $-115.05M | $-4.23M | $-4.30M |
| High Forecast | $-382.03M | $-329.98M | $-29.04M | $-40.58M | $-351.48M | $-307.45M | $-55.57M | $-67.00M | $-395.65M | $-212.09M | $-32.51M | $-23.61M | $-559.45M | $-128.96M | $-77.89M | $-298.26M | $-1.27B | $-859.55M | $-998.59M | $4.43B | $-1.66B | $-1.48B | $-1.03B | $1.24B | $-68.10M | $-19.65M | $-6.71M | $-92.04M | $-4.23M | $-4.30M |
| Low Forecast | $-382.03M | $-329.98M | $-29.04M | $-40.58M | $-351.48M | $-307.45M | $-55.57M | $-67.00M | $-395.65M | $-377.74M | $-32.51M | $-23.61M | $-737.45M | $-486.79M | $-77.89M | $-298.26M | $-1.27B | $-859.55M | $-998.59M | $2.95B | $-1.66B | $-1.48B | $-1.03B | $829.90M | $-68.10M | $-19.65M | $-6.71M | $-138.06M | $-4.23M | $-4.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.74% | 23.97% | 0.97% | -1.24% | -1.56% | -2.45% | 1.17% | -3.32% | -2.45% | -3.06% | 1.23% | 3.81% | 11.27% | 15.97% | 1.00% | 26.53% | 26.64% |
6 analysts predict MRNA's average Quarter EBITDA for Mar 23 to be $-298.26M, with a high of $-298.26M and a low of $-298.26M. This is -118.88% lower than Moderna's previous annual EBITDA (Dec 22) of $1.58B.
Moderna Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 9 | 10 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.63B | $-1.38B | $79.00M | $1.47B | $1.04B | $2.20B | $3.66B | $4.87B | $3.33B | $2.78B | $1.22B | $-272.49M | $-233.64M | $-116.71M | $-124.23M | $-123.12M | $-123.19M |
| Avg Forecast | $-340.03M | $-431.96M | $-1.16B | $-1.09B | $-481.83M | $-636.22M | $-1.18B | $-1.15B | $-635.19M | $-749.03M | $-1.29B | $3.79B | $-378.92M | $-742.00M | $-1.51B | $3.44B | $4.60B | $1.27B | $1.76B | $3.13B | $3.83B | $3.45B | $2.29B | $991.10M | $-131.52M | $-145.22M | $-135.45M | $-124.23M | $-161.28M | $-167.86M |
| High Forecast | $-340.03M | $-431.96M | $-1.16B | $-1.09B | $-481.83M | $-636.22M | $-1.18B | $-1.15B | $-635.19M | $-384.32M | $-1.29B | $4.55B | $1.56B | $-257.01M | $-1.51B | $4.13B | $5.52B | $1.27B | $1.76B | $3.76B | $3.83B | $3.45B | $2.29B | $1.19B | $-131.52M | $-145.22M | $-135.45M | $-99.38M | $-161.28M | $-167.86M |
| Low Forecast | $-340.03M | $-431.96M | $-1.16B | $-1.09B | $-481.83M | $-636.22M | $-1.18B | $-1.15B | $-635.19M | $-1.05B | $-1.29B | $3.03B | $-1.32B | $-1.43B | $-1.51B | $2.75B | $3.68B | $1.27B | $1.76B | $2.50B | $3.83B | $3.45B | $2.29B | $792.88M | $-131.52M | $-145.22M | $-135.45M | $-149.08M | $-161.28M | $-167.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.89% | 0.91% | 0.02% | 0.32% | 0.82% | 1.25% | 1.17% | 1.27% | 0.97% | 1.22% | 1.23% | 2.07% | 1.61% | 0.86% | 1.00% | 0.76% | 0.73% |
Moderna's average Quarter net income forecast for Jun 23 is $-1.51B, with a range of $-1.51B to $-1.51B. MRNA's average Quarter net income forecast represents a -2012.56% decrease compared to the company's last Quarter net income of $79.00M (Mar 23).
Moderna SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 9 | 10 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $442.00M | $332.00M | $305.00M | $375.00M | $278.00M | $211.00M | $268.00M | $201.00M | $168.00M | $121.00M | $77.00M | $78.99M | $48.54M | $36.62M | $24.11M | $25.63M | $28.19M |
| Avg Forecast | $992.32M | $857.12M | $75.43M | $105.41M | $912.94M | $798.60M | $144.35M | $174.02M | $1.03B | $817.64M | $84.44M | $61.33M | $1.65B | $910.43M | $202.32M | $252.33M | $190.06M | $2.32B | $2.69B | $229.39M | $4.47B | $4.00B | $2.77B | $62.50M | $183.74M | $53.00M | $18.09M | $11.57M | $11.42M | $11.60M |
| High Forecast | $992.32M | $857.12M | $75.43M | $105.41M | $912.94M | $798.60M | $144.35M | $174.02M | $1.03B | $981.17M | $84.44M | $61.33M | $1.92B | $1.26B | $202.32M | $302.80M | $228.07M | $2.32B | $2.69B | $275.27M | $4.47B | $4.00B | $2.77B | $75.00M | $183.74M | $53.00M | $18.09M | $11.57M | $11.42M | $11.60M |
| Low Forecast | $992.32M | $857.12M | $75.43M | $105.41M | $912.94M | $798.60M | $144.35M | $174.02M | $1.03B | $550.89M | $84.44M | $61.33M | $1.45B | $334.98M | $202.32M | $201.87M | $152.05M | $2.32B | $2.69B | $183.52M | $4.47B | $4.00B | $2.77B | $50.00M | $183.74M | $53.00M | $18.09M | $11.57M | $11.42M | $11.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 1.64% | 1.21% | 1.97% | 0.12% | 0.08% | 1.17% | 0.04% | 0.04% | 0.04% | 1.23% | 0.43% | 0.92% | 2.02% | 2.08% | 2.24% | 2.43% |
Moderna's average Quarter SG&A projection for Dec 23 is $1.65B, based on 10 Wall Street analysts, with a range of $1.45B to $1.92B. The forecast indicates a 273.60% rise compared to MRNA last annual SG&A of $442.00M (Sep 23).
Moderna EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 9 | 10 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-9.53 | $-3.62 | $0.20 | $3.81 | $2.67 | $5.55 | $9.09 | $12.02 | $8.27 | $6.93 | $3.05 | $-0.69 | $-0.59 | $-0.31 | $-0.35 | $-0.37 | $-0.37 |
| Avg Forecast | $-0.89 | $-1.12 | $-3.02 | $-2.83 | $-1.25 | $-1.66 | $-3.07 | $-3.00 | $-1.65 | $-1.95 | $-3.35 | $-3.56 | $-0.99 | $-1.93 | $-3.93 | $-1.75 | $4.60 | $3.30 | $4.58 | $5.37 | $9.96 | $8.97 | $5.96 | $2.43 | $-0.34 | $-0.38 | $-0.35 | $-0.35 | $-0.42 | $-0.44 |
| High Forecast | $-0.89 | $-1.12 | $-3.02 | $-2.83 | $-1.25 | $-1.66 | $-3.07 | $-3.00 | $-1.65 | $-1.00 | $-3.35 | $-3.56 | $4.07 | $-0.67 | $-3.93 | $-1.75 | $4.60 | $3.30 | $4.58 | $5.37 | $9.96 | $8.97 | $5.96 | $2.43 | $-0.34 | $-0.38 | $-0.35 | $-0.35 | $-0.42 | $-0.44 |
| Low Forecast | $-0.89 | $-1.12 | $-3.02 | $-2.83 | $-1.25 | $-1.66 | $-3.07 | $-3.00 | $-1.65 | $-2.75 | $-3.35 | $-3.56 | $-3.44 | $-3.72 | $-3.93 | $-1.75 | $4.60 | $3.30 | $4.58 | $5.37 | $9.96 | $8.97 | $5.96 | $2.43 | $-0.34 | $-0.38 | $-0.35 | $-0.35 | $-0.42 | $-0.44 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.93% | 0.92% | -0.11% | 0.83% | 0.81% | 1.21% | 1.69% | 1.21% | 0.92% | 1.16% | 1.25% | 2.01% | 1.56% | 0.88% | 0.99% | 0.88% | 0.85% |
According to 6 Wall Street analysts, Moderna's projected average Quarter EPS for Jun 23 is $-3.93, with a low estimate of $-3.93 and a high estimate of $-3.93. This represents a -2067.34% decrease compared to MRNA previous annual EPS of $0.20 (Mar 23).
Moderna Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| CVAC | CureVac | $2.71 | $29.00 | 970.11% | Buy |
| NTLA | Intellia Therapeutics | $15.14 | $118.84 | 684.94% | Buy |
| NVAX | Novavax | $9.12 | $58.00 | 535.96% | Buy |
| EDIT | Editas Medicine | $2.88 | $13.50 | 368.75% | Buy |
| MRNA | Moderna | $53.54 | $143.90 | 168.77% | Hold |
| BEAM | Beam Therapeutics | $24.36 | $64.20 | 163.55% | Buy |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| DNA | Ginkgo Bioworks | $7.63 | $7.34 | -3.80% | Buy |
| VRTX | Vertex Pharmaceuticals | $472.80 | $403.75 | -14.60% | Buy |
MRNA Forecast FAQ
Is Moderna a good buy?
No, according to 25 Wall Street analysts, Moderna (MRNA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 36.00% of MRNA's total ratings.
What is MRNA's price target?
Moderna (MRNA) average price target is $143.9 with a range of $55 to $304, implying a 168.77% from its last price of $53.54. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Moderna stock go up soon?
According to Wall Street analysts' prediction for MRNA stock, the company can go up by 168.77% (from the last price of $53.54 to the average price target of $143.9), up by 467.80% based on the highest stock price target, and up by 2.73% based on the lowest stock price target.
Can Moderna stock reach $80?
MRNA's average twelve months analyst stock price target of $143.9 supports the claim that Moderna can reach $80 in the near future.
What is Moderna's current price target trend?
2 Wall Street analysts forecast a $55 price target for Moderna (MRNA) this month, up 2.73% from its last price of $53.54. Compared to the last 3 and 12 months, the average price target increased by 100.28% and increased by 138.96%, respectively.
What are Moderna's analysts' financial forecasts?
Moderna's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.09B (high $3.09B, low $3.09B), average EBITDA is $-781M (high $-781M, low $-781M), average net income is $-3.449B (high $-3.449B, low $-3.449B), average SG&A $2.03B (high $2.03B, low $2.03B), and average EPS is $-8.982 (high $-8.982, low $-8.982). MRNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.09B (high $3.09B, low $3.09B), average EBITDA is $-782M (high $-782M, low $-782M), average net income is $-3.016B (high $-3.016B, low $-3.016B), average SG&A $2.03B (high $2.03B, low $2.03B), and average EPS is $-7.854 (high $-7.854, low $-7.854).
Did the MRNA's actual financial results beat the analysts' financial forecasts?
Based on Moderna's last annual report (Dec 2022), the company's revenue was $19.26B, beating the average analysts forecast of $16.84B by 14.36%. Apple's EBITDA was $9.77B, beating the average prediction of $564.19M by 1631.33%. The company's net income was $8.36B, missing the average estimation of $10.76B by -22.28%. Apple's SG&A was $1.13B, missing the average forecast of $5.43B by -79.16%. Lastly, the company's EPS was $21.26, beating the average prediction of $17.86 by 19.07%. In terms of the last quarterly report (Sep 2023), Moderna's revenue was $1.83B, beating the average analysts' forecast of $1.38B by 32.25%. The company's EBITDA was $-2.012B, beating the average prediction of $-351M by 474.02%. Moderna's net income was $-3.63B, beating the average estimation of $-742M by 389.22%. The company's SG&A was $442M, missing the average forecast of $910.43M by -51.45%. Lastly, the company's EPS was $-9.53, beating the average prediction of $-1.932 by 393.19%